Zurück zu Projekte

12803.1;11 VOUCH-LS

Innovative 'armed' antibodies

Zusammenfassung

Innovative 'armed' antibodies

Weitere Texte

Abstract

Monoclonal antibodies represent the largest and fastest growing class of biotechnology products. While conventional antibody products are based on intact IgG, there is a growing trend towards ¿arming¿ antibodies with therapeutic payloads. The Philogen group is one of the pioneers in the engineering of armed human antibodies for therapeutic applications. In order to retain and consolidate its leadership in the field, we need to stay ahead of competition and explore innovative immunocytokines, alongside with their possible clinical application areas.

Beteiligte

Dario Neri

Kontaktperson

dario.neri@pharma.ethz.ch

ETH Zürich Inst. of Pharmac. Sciences Dario Neri Wolfgang-Paulistrasse 10 HCI G496 8093 Zürich ZH CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2012-03-31
Enddatum
2015-11-11
Bewilligte Gesamtkosten
CHF 347744.00
Sektion
5 KTI
NABS Politikbereich
Nicht aufteilbare / nicht zuteilbare Forschung

Forschungsdisziplinen

  • T490 Biotechnology 100.0%